#United States #Class Action #San Francisco #Hagens Berman #ADMA Biologics

Important Alert for ADMA Biologics Investors

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) are facing a crucial deadline. Hagens Berman, a prominent law firm specializing in securities litigation, is urging those affected by alleged securities fraud to come forward before August 10, 2026. This warning comes in light of a class action lawsuit that accuses the company of misrepresenting its financial health and practices.

Background of the Lawsuit

The class action filing centers on claims that ADMA Biologics engaged in misleading actions, which artificially inflated the company's stock price. The allegations include:

• - Undisclosed related-party transactions that raised concern about the integrity of their financial practices.
• - Use of channel stuffing methods to create an illusion of increased revenue.
• - Inadequate internal controls that failed to ensure accurate financial reporting.

As a result of these alleged misrepresentations, statements from ADMA about its business operations and overall prospects were deemed materially false and misleading.

Timeline of Events

Class Period

The alleged fraudulent activities reportedly occurred between August 9, 2024, and March 25, 2026.

Corrective Events and Market Reactions

The lawsuit highlights significant events that triggered a dramatic decline in stock value, including:

• - On March 24, 2026, Culper Research published a report revealing claims of channel stuffing and undisclosed relationships with a distributor, leading to a staggering loss of 31.6% in stock value over two days.
• - Following this, on March 26, ADMA issued a press release acknowledging it would review the allegations, but a downgrade by Cantor Fitzgerald further diminished investor confidence, resulting in a 13.9% decline in share price.

These occurrences prompted widespread concern among investors, exposing them to substantial financial losses.

What Affected Investors Should Do

If you are an investor who incurred significant losses related to ADMA Biologics, Hagens Berman wants to hear from you. The firm is not only looking for individuals who have faced financial detriment but also those who possess insider information about the alleged misconduct. Whistleblowers providing original information may be eligible for rewards under the SEC Whistleblower program.

Next Steps

• - Submit your information to Hagens Berman at their dedicated webpage if you have insights or substantial loss claims to share.
• - Reach out directly via email or phone to assist in their investigation, possibly facilitating justice for those affected by the alleged fraud.

As a key player in corporate accountability, Hagens Berman has garnered over $2.9 billion in compensations on behalf of harmed investors and consumers. Their team seeks to ensure that all responsible parties are held accountable for these alleged wrongdoings.

For ongoing updates regarding this case and more information, visit Hagens Berman’s official site or follow their news updates online.

Conclusion

The ADMA Biologics lawsuit serves as a cautionary tale in the investment landscape. Investors are reminded of the importance of transparent practices and the need for thorough due diligence before committing their capital. If you or a loved one has been involved with ADMA Biologics during the relevant class period, now is the time to act before the impending deadline.